Takeda-partnered Evox signs up to $1.2B pact with Lilly; New liquid biopsy company launches with $12M Series A
→ Oxford spinout Evox — one of a handful of players that are using tiny exosomes to deliver a therapeutic payload where needed, including to the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
